Comparison of the Efficacy of a Protocol for the Withdrawal of Neurosedation From the Usual Strategy in Cerebroses

Centre Hospitalier Universitaire, Amiens8 enrolled

Overview

The withdrawal syndrome in benzodiazepines and morphine is common in intensive care, the incidence is estimated at 32.1%. Cerebrospatized patients are probably more prone to withdrawal because they require high doses of sedation. Moreover, this syndrome is probably deleterious on the cerebral hemodynamics (high point of the therapeutic management).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

OTHER

Masking

NONE

Enrollment

Conditions

Withdrawal Syndrome Cerebral Lesion

Interventions

Variation of Jasinski score between H0 (stop of sedatives) and H6OTHER

To compare the effectiveness of a withdrawal management protocol with the usual management in cerebral patients (Subarachnoid haemorrhage (HSA), stroke and head trauma (CT))

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Major Patient * Admitted in Neuroreanimation * Cerebroséé (TC-HSA-AVC) * Mono or multi failing * After a neurosedation ≥ 3 days by hypnotic type benzodiazepine (Midazolam®) and morphinomimetic (Sufentanyl®) in IVSE * Affiliation to Social Security * Agreement of the person of confidence Exclusion Criteria: * Addiction to opiates, cocaine or cannabis * Neurological Pathology Before Hospitalization * Patient suffering from cardiac arrest * Pregnant woman * Sedation window * Patient under tutelage or curatorship or deprived of public law

Locations (1)

CHU Amiens Picardie

Amiens, Picardie, France

Outcomes

Primary Outcomes

A variation of the Jasinski score between H0 (stop sedation) and H6. This score measures the signs of withdrawal

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.